Roivant Sciences

ROIV | NASDAQ | 3 Followers

$11.19

1.77%

$0.20

Overview Metrics Financials

Fair Price

$2.93

Overvalued by 27.8%

To display the fair price of a share, you need to be a member of Bulios Black.

Company Quality

Profitability Score

17/100

Solvency Score

75/100

Dividends

Dividends data currently unavailable.

Earnings

8/6/2025

in 64 days

Revenue est.

EPS est.

My Notes

You haven't added any notes for this stock yet. Use this space to record your insights or strategies.

Profile

Healthcare

Sector

Biotechnology

Industry

Mr. Matthew Gline

CEO

908

Employees

London

Headquarters

Country

Roivant Sciences (ROIV) is a biotechnology company specializing in the development and commercialization of innovative drugs and therapies. Utilizing advanced technologies and a strategic approach to research and development, Roivant Sciences focuses on rapidly bringing new treatment options to market. The company is known for its unique model and portfolio, which includes various therapeutic areas. Roivant Sciences is also engaged in partnerships with other organizations to accelerate healthcare innovations. Roivant Sciences (ROIV) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on innovation and research.

Key Metrics TTM

Valuation

Market cap.

$7.5B

Enterprise Value

$5.6B

Price to Earnings

-68.11

Price to Sales

76.58

Price to Book

1.53

Price to Cash Flow

-9.58

Profitability

Return on Assets

-2.01%

Return on Equity

-2.10%

Return on Invested Capital

-17.42%

Gross Margin

89.03%

Operating Margin

-1,027.40%

Net Margin

-119.54%

Liquidity

Quick Ratio

37.91

Current Ratio

37.91

Cash Ratio

14.07

Inventory Turnover

0.00

Asset Turnover

0.02

Total Liabilities

$256M

Solvency

Debt to Assets

0.02

Debt to Equity

N/A

Interest Coverage

-48.72

Equity Ratio

0.96

Long-term Debt to Cap.

0.00

Altman Z-Score

22.60

Performance

Performance data currently unavailable.

Earnings Waterfall

Debt level and coverage

Debt level and coverage data currently unavailable.

Earnings

Feed

There are no posts to show right now.